- Report
- February 2026
- 181 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 196 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 194 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 402 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 192 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 196 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 187 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 193 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 411 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- August 2025
- 184 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- January 2026
- 120 Pages
Global
From €4160EUR$4,750USD£3,611GBP
- Report
- November 2025
- 200 Pages
Global
From €6963EUR$7,950USD£6,043GBP
- Drug Pipelines
- April 2025
- 80 Pages
Global
From €1752EUR$2,000USD£1,520GBP
- Report
- January 2026
- 130 Pages
Global
From €4160EUR$4,750USD£3,611GBP
- Report
- January 2026
- 159 Pages
Global
From €4160EUR$4,750USD£3,611GBP
- Report
- June 2025
- 400 Pages
Global
From €4334EUR$4,949USD£3,762GBP
- Drug Pipelines
- April 2025
- 400 Pages
Global
From €4379EUR$5,000USD£3,801GBP
- Report
- January 2026
- 150 Pages
Global
From €3459EUR$3,950USD£3,003GBP
- Report
- January 2026
- 128 Pages
Global
From €3459EUR$3,950USD£3,003GBP
- Report
- January 2026
- 149 Pages
Global
From €3459EUR$3,950USD£3,003GBP

The Viral Vector market is a subset of the biotechnology industry that focuses on the development and production of viral vectors for gene therapy. Viral vectors are modified viruses that are used to deliver genetic material into cells, allowing for the expression of a desired gene. This technology has been used to treat a variety of diseases, including cancer, genetic disorders, and infectious diseases.
Viral vectors are produced through a variety of methods, including recombinant DNA technology, synthetic biology, and cell-based systems. The production of viral vectors requires specialized equipment and expertise, making it a highly specialized field.
The Viral Vector market is highly competitive, with a number of companies offering products and services. Some of the major players in the market include Novartis, Merck, Pfizer, AstraZeneca, and Sanofi. Additionally, there are a number of smaller companies that specialize in the production of viral vectors, such as Viralgen, Oxford BioMedica, and Vigene Biosciences. Show Less Read more